Nicotinic Modulation of the Default Network

Status Completed

Clinical Trial Summary

Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and schizophrenia, display abnormal regulation of the so-called default network of resting brain function that maintains internally directed thought when the mind is free to wander. There is indication that nicotine may improve attention by aiding the deactivation of the default network, and this mechanism may be of therapeutic benefit for the above disease states. The current project aims at providing a proof of concept by demonstrating that nicotinic drugs modulate default network function. The nicotinic agonist nicotine is hypothesized to improve attention by facilitating the down-regulation of default network activity, and the nicotinic antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation of default network activity during attentional task performance.

Clinical Trial Description

This study only enrolls healthy non-smokers. Participants perform attention tasks while undergoing functional Magnetic Resonance Imaging on three separate days. Across the three days, three difference conditions are tested in a double-blind manner, in randomized order. In all test sessions, participants receive a skin patch and swallow a capsule. In one session, both are a placebo. In another, the patch is a low-dose nicotine patch, and the capsule is a placebo. In another session, the patch is a placebo and the capsule contains a low dose of mecamylamine. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01223404
Study type	Interventional
Source	University of Maryland, Baltimore
Contact
Status	Completed
Phase	N/A
Start date	October 2010
Completion date	September 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03785171` - Predicative Value of Multimodal MRI in Moyamoya Disease
Not yet recruiting	`NCT03726788` - Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis	Phase 2
Active, not recruiting	`NCT01956409` - Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis	Phase 4
Completed	`NCT01660841` - Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging	Phase 3
Recruiting	`NCT03635619` - The Application of 3T MRI in Esophageal Cancer
Recruiting	`NCT03658343` - T2* MRI Analysis for Sarcoma	N/A
Recruiting	`NCT04555642` - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Active, not recruiting	`NCT03441867` - Neuroimaging Biomarker for Seizures	N/A
Recruiting	`NCT04850001` - Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
Not yet recruiting	`NCT05816213` - Point-of-care Low-field MRI in Acute Stroke
Active, not recruiting	`NCT05498623` - MR Fingerprinting for Diagnostic of Prostate Cancer
Recruiting	`NCT04996615` - Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
Recruiting	`NCT04257747` - Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI	N/A
Recruiting	`NCT05889117` - Brain Stimulation for Concussion	N/A
Completed	`NCT02540967` - Drug Use Investigation of Gadovist.
Completed	`NCT05103189` - 4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension	N/A
Completed	`NCT02567318` - Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?	N/A
Recruiting	`NCT02834585` - Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)	N/A
Active, not recruiting	`NCT02446665` - Disease Status in Primary Sclerosing Cholangitis by Elastography	N/A
Completed	`NCT01721785` - Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer	N/A